PE20090878A1 - Composicion orodispersable sin mal olor o mal sabor que comprende acidos grasos poliinsaturados - Google Patents

Composicion orodispersable sin mal olor o mal sabor que comprende acidos grasos poliinsaturados

Info

Publication number
PE20090878A1
PE20090878A1 PE2008001804A PE2008001804A PE20090878A1 PE 20090878 A1 PE20090878 A1 PE 20090878A1 PE 2008001804 A PE2008001804 A PE 2008001804A PE 2008001804 A PE2008001804 A PE 2008001804A PE 20090878 A1 PE20090878 A1 PE 20090878A1
Authority
PE
Peru
Prior art keywords
fatty acids
bad
composition
dispersible
polyinsaturated
Prior art date
Application number
PE2008001804A
Other languages
English (en)
Inventor
Catherine Kabaradjian
Original Assignee
Bayer Consumer Care Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Consumer Care Ag filed Critical Bayer Consumer Care Ag
Publication of PE20090878A1 publication Critical patent/PE20090878A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/84Flavour masking or reducing agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) ACIDOS GRASOS POLIINSATURADOS (PUFA) TALES COMO ACIDOS GRASOS OMEGA-3, ACIDO EICOSAPENTENOICO (EPA), ACIDO LINOLEICO, ACEITE DE PESCADO, ENTRE OTROS, EN UNA CANTIDAD DE 5% A 70% EN PESO DE LA COMPOSICION; B) UN DISGREGANTE QUE ES UNA DISPERSION SOLIDA QUE COMPRENDE CELULOSA MICROCRISTALINA, CROSPOVIDONA Y FOSFATO DE CALCIO DIBASICO DISPERSOS EN UNA MEZCLA DE MANITOL Y XILITOL; Y C) UN MINERAL Y/O VITAMINA ADICIONAL. DICHA COMPOSICION SE PRESENTA EN FORMA DE COMPRIMIDO ORODISPERSABLE CON TIEMPO DE DISGREGACION MENOR O IGUAL A 100 SEGUNDOS SIENDO UTIL EN PREVENIR O REDUCIR EL RIESGO DE ENFERMEDADES ATEROSCLEROTICAS, CARDIOVASCULARES, ALIVIAR TRASTORNOS HORMONALES
PE2008001804A 2007-10-30 2008-10-21 Composicion orodispersable sin mal olor o mal sabor que comprende acidos grasos poliinsaturados PE20090878A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291305 2007-10-30

Publications (1)

Publication Number Publication Date
PE20090878A1 true PE20090878A1 (es) 2009-07-03

Family

ID=40279125

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001804A PE20090878A1 (es) 2007-10-30 2008-10-21 Composicion orodispersable sin mal olor o mal sabor que comprende acidos grasos poliinsaturados

Country Status (15)

Country Link
US (1) US20150038583A9 (es)
EP (1) EP2214628B1 (es)
AR (1) AR069129A1 (es)
AT (1) ATE529095T1 (es)
AU (1) AU2008317921B2 (es)
BR (1) BRPI0818797A2 (es)
CA (1) CA2703818C (es)
ES (1) ES2373624T3 (es)
MX (1) MX2010003843A (es)
PE (1) PE20090878A1 (es)
PL (1) PL2214628T3 (es)
RU (1) RU2493842C2 (es)
TW (1) TW200936164A (es)
UY (1) UY31411A1 (es)
WO (1) WO2009056248A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784904B2 (en) 2008-04-10 2014-07-22 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essential fatty acids derived from perilla seed: composition of matter, manufacturing process and use
US9770047B2 (en) 2008-04-10 2017-09-26 U.S. Nutraceuticals, LLC Perilla seed composition
US8586104B2 (en) 2008-04-10 2013-11-19 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica L. seed: composition of matter, manufacturing process and use
US9610313B2 (en) 2008-04-10 2017-04-04 U.S. Nutraceuticals Eye health composition and method using plant derived seed extract rich in essential fatty acids derived from perilla seed and carotenoids
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
WO2016205754A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
CN110237261A (zh) * 2019-07-30 2019-09-17 珠海市东辰制药有限公司 一种复合崩解剂及其制备方法
US12599544B2 (en) 2024-05-09 2026-04-14 Alsteni Medical, Inc. Intraoral gastrointestinal access device and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3702031A1 (de) * 1987-01-24 1988-08-04 Basf Ag Verfahren zur herstellung von mikrodispersen fischoelpraeparaten
JPH08259943A (ja) * 1995-03-21 1996-10-08 Nippon Suisan Kaisha Ltd 乳化油脂用酸化安定剤
US6630192B2 (en) * 1995-04-07 2003-10-07 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
AU2006211023B2 (en) * 2005-02-03 2012-05-24 Takeda Nycomed As Fast wet-massing method for the preparation of calcium-containing compositions

Also Published As

Publication number Publication date
US20150038583A9 (en) 2015-02-05
AR069129A1 (es) 2009-12-30
BRPI0818797A2 (pt) 2014-10-07
MX2010003843A (es) 2010-07-30
RU2010121715A (ru) 2011-12-10
CA2703818A1 (en) 2009-05-07
CA2703818C (en) 2016-01-05
UY31411A1 (es) 2009-05-29
AU2008317921A1 (en) 2009-05-07
ES2373624T3 (es) 2012-02-07
PL2214628T3 (pl) 2012-03-30
RU2493842C2 (ru) 2013-09-27
TW200936164A (en) 2009-09-01
ATE529095T1 (de) 2011-11-15
EP2214628B1 (en) 2011-10-19
AU2008317921B2 (en) 2014-04-03
US20100216885A1 (en) 2010-08-26
WO2009056248A1 (en) 2009-05-07
EP2214628A1 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
PE20090878A1 (es) Composicion orodispersable sin mal olor o mal sabor que comprende acidos grasos poliinsaturados
McNamara et al. Omega-3 fatty acid deficiency increases constitutive pro-inflammatory cytokine production in rats: relationship with central serotonin turnover
UA102478C2 (en) Capsule composition
EP3713550A2 (en) Multifunctional formulations and methods to control dermatitis and pruritus
Jang et al. Perilla oil improves blood flow through inhibition of platelet aggregation and thrombus formation
Wu et al. Alleviation of N-methyl-D-aspartate receptor-dependent long-term depression via regulation of the glycogen synthase kinase-3β pathway in the amygdala of a valproic acid-induced animal model of autism
CA2880708C (en) Plant extracts for improving cognitive health and function
PE20060016A1 (es) Solidos supersaturados estabilizados de drogas lipofilicas
WO2012013331A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
Cicero Nutraceuticals and dietary supplements to improve quality of life and outcomes in heart failure patients
UY31410A1 (es) Composicion que comprende acidos grasos poliinsaturados y carbon vegetal activado
Kumar et al. Omega-3 fatty acids could alleviate the risks of traumatic brain injury–a mini review
Strokin et al. Neuroprotection of rat hippocampal slices exposed to oxygen–glucose deprivation by enrichment with docosahexaenoic acid and by inhibition of hydrolysis of docosahexaenoic acid-containing phospholipids by calcium independent phospholipase A2
MA38688B1 (fr) Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d
CL2019000607A1 (es) Composición para aplicación tópica con actividad antifúngica.
WO2011060944A3 (en) Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
Tang et al. An Ω-3 fatty acid-deficient diet during gestation induces depressive-like behavior in rats: the role of the hypothalamo–pituitary–adrenal (HPA) system
JP6663993B2 (ja) 安定性が向上し、取り込みが改善されたホノキオール及びマグノロール製剤、並びにそれらの使用方法
Wang et al. Antarctic krill oil exhibited synergistic effects with nobiletin and theanine in ameliorating memory and cognitive deficiency in SAMP8 mice: Applying the perspective of the sea–land combination to retard brain aging
CO6341531A2 (es) Producto alimenticio de acidos grasos con base de chia, rico en omega-3, con buena estabilidad
ATE443515T1 (de) Omega-3-fettsäuren und omega-6-fettsäuren enthaltende zusammensetzung
CN1927050B (zh) Dha微胶囊食品添加剂、dha软胶囊保健品及其应用
US20190321320A1 (en) Prevention of psychotic disorders and/or treatment of psychotic symptoms
Raghavendra et al. Eugenol and n-3 rich garden cress seed oil as modulators of platelet aggregation and eicosanoids in Wistar albino rats
ITFI20090189A1 (it) Estratto di rhodiola per l'uso nel trattamento farmacologico di binge eating disorder e bulimia nervosa.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal